AU3660700A - N-(2-(4-aminophyl)ethyl)-2,3-dihydro-1,4-benzodioxine-2-met hanamine, production and therapeutic use thereof - Google Patents

N-(2-(4-aminophyl)ethyl)-2,3-dihydro-1,4-benzodioxine-2-met hanamine, production and therapeutic use thereof

Info

Publication number
AU3660700A
AU3660700A AU36607/00A AU3660700A AU3660700A AU 3660700 A AU3660700 A AU 3660700A AU 36607/00 A AU36607/00 A AU 36607/00A AU 3660700 A AU3660700 A AU 3660700A AU 3660700 A AU3660700 A AU 3660700A
Authority
AU
Australia
Prior art keywords
aminophyl
hanamine
benzodioxine
dihydro
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36607/00A
Inventor
Antonio Almario Garcia
Danielle De Peretti
Yannick Evanno
Jean-Francois Gibert
Michel Peynot
Maria-Carmen Renones
Jocelyne Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU3660700A publication Critical patent/AU3660700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
AU36607/00A 1999-03-30 2000-03-27 N-(2-(4-aminophyl)ethyl)-2,3-dihydro-1,4-benzodioxine-2-met hanamine, production and therapeutic use thereof Abandoned AU3660700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9903936A FR2791675B1 (en) 1999-03-30 1999-03-30 DERIVATIVES OF N- [2- (4-AMINOPHENYL) ETHYL] -2,3-DIHYDRO-1,4- BENZODIOXINNE-2-METHANAMINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR9903936 1999-03-30
PCT/FR2000/000762 WO2000058301A1 (en) 1999-03-30 2000-03-27 N-[2-(4-aminophyl)ethyl]-2,3-dihydro-1,4-benzodioxine-2-methanamine, production and therapeutic use thereof

Publications (1)

Publication Number Publication Date
AU3660700A true AU3660700A (en) 2000-10-16

Family

ID=9543788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36607/00A Abandoned AU3660700A (en) 1999-03-30 2000-03-27 N-(2-(4-aminophyl)ethyl)-2,3-dihydro-1,4-benzodioxine-2-met hanamine, production and therapeutic use thereof

Country Status (6)

Country Link
AU (1) AU3660700A (en)
CO (1) CO5170535A1 (en)
FR (1) FR2791675B1 (en)
PE (1) PE20001598A1 (en)
UY (1) UY26085A1 (en)
WO (1) WO2000058301A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
BRPI0608353A2 (en) 2005-02-17 2009-12-01 Wyeth Corp indole, benzothiophene, benzofuran and indene cycloalkyl fused derivatives
MX2007013163A (en) 2005-04-22 2008-01-21 Wyeth Corp Chromane and chromene derivatives and uses thereof.
MX2007013151A (en) * 2005-04-22 2008-01-16 Wyeth Corp Benzodioxane and benzodioxolane derivatives and uses thereof.
AR060493A1 (en) * 2006-04-18 2008-06-18 Wyeth Corp DERIVATIVES OF BENZODIOXAN AND BENZODIOXOLAN. OBTAINING PROCESSES.
TW200823187A (en) * 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
JP2011519839A (en) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ Modulator of dopamine neurotransmission
AU2009242092A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
CN102015674B (en) 2008-04-29 2014-10-29 Nsab神经研究瑞典公司分公司 Modulators of dopamine neurotransmission

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE635203A (en) * 1962-07-20
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives

Also Published As

Publication number Publication date
UY26085A1 (en) 2000-10-31
PE20001598A1 (en) 2001-04-01
FR2791675A1 (en) 2000-10-06
WO2000058301A1 (en) 2000-10-05
FR2791675B1 (en) 2001-05-04
CO5170535A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AU763356C (en) Fused-ring compounds and use thereof as drugs
AU4796700A (en) Ureido-substituted cyclic amine derivatives and their use as drug
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
AU3957600A (en) Piperidyl-imidazole derivatives, their preparations and therapeutic uses
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU4143300A (en) Cyclic amide compounds, process for the preparation of the same and uses thereof
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU2003255645A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
SI1268522T1 (en) Novel lhrh-antagonists, production and use thereof as medicament
AU2003269018A1 (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
AU3660700A (en) N-(2-(4-aminophyl)ethyl)-2,3-dihydro-1,4-benzodioxine-2-met hanamine, production and therapeutic use thereof
AU6635800A (en) Pyridomorphinans, thienomoprhinans and use thereof
AU2002308891A1 (en) Novel heterocyclic derivatives and medicinal use thereof
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.
AU3971500A (en) Indazole derivatives, preparation and therapeutic application thereof
AU2001260110A1 (en) Novel LHRH-antagonists, Production and Use Thereof as Medicament
AU1651001A (en) Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof
AU2002308889A1 (en) Novel heterocyclic compound and medicinal use thereof
AU6846500A (en) Novel 8-carbonyl chroman derivatives, preparation and therapeutic use thereof
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
HUP0203468A3 (en) Betha-d-5-thioxylose derivatives, preparation method and therapeutic use thereof
AU5524400A (en) Novel 6-amino-uracil derivatives, preparation and use thereof
AU3971800A (en) 2-alkoxy-cyclobutene-3,4-dione derivatives, preparation and therapeutic use thereof
AU2001237518A1 (en) Polyfluoroalkylimidazole derivatives, their preparation and therapeutic application
AU5848400A (en) Novel physiologically active substance, process for producing the same and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase